Serum apolipoprotein-A1 as a possible biomarker for monitoring treatment of canine leishmaniosis
No Thumbnail Available
Date
2016-10-10
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
The aims of this study were: the identification of proteins differentially represented in the serum proteome of dogs with leishmaniosis after treatment and the verification of one selected protein as a possible biomarker for treatment monitoring. Serum samples from five dogs with leishmaniosis, before and after treatment were pooled into two groups and analysed using 2-dimensional electrophoresis followed by mass spectrometry analysis (MS). The MS analysis allowed the identification of 8 proteins differently expressed. APO-A1 was selected and an immunoturbidimetric assay was validated for its measurement in dogs. Significantly decreased concentrations of APO-A1 in dogs with leishmaniosis and a significant increase after a good response to the treatment were observed, suggesting that APO-A1 could be a potential biomarker of treatment monitoring with the advantages of an automated measurement.
Description
Keywords
Immunology, Microbiology, Veterinary sciences, Leishmaniosis, Dogs, Apolipoprotein A1, Treatment monitoring, Visceral leishmaniasis, Proteins, Identification, Proteomics, Diagnosis
Citation
Escribano, D. vd. (2016). "Serum apolipoprotein-A1 as a possible biomarker for monitoring treatment of canine leishmaniosis". Comparative Immunology Microbiology and Infectious Diseases, 49, 82-87.